| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
AEterna Zentaris, Inc. (TSE: AEZ)
AEZ Technical Analysis
3
| As on 28th Feb 2017 AEZ Share Price closed @ 4.02 and we RECOMMEND Sell for LONG-TERM with Stoploss of 4.56 & Sell for SHORT-TERM with Stoploss of 4.18 we also expect STOCK to react on Following IMPORTANT LEVELS. |
AEZ Share Price
| Open | 4.04 | Change | Price | % |
| High | 4.04 | 1 Day | 0.02 | 0.50 |
| Low | 4.00 | 1 Week | 0.00 | 0.00 |
| Close | 4.02 | 1 Month | 0.00 | 0.00 |
| Volume | 23845 | 1 Year | -0.77 | -16.08 |
| 52 Week High 5.70 | 52 Week Low 3.10 | ||||
TSE Canada Most Active Stocks
| BIN | 41.40 | -1.62% |
| LSG | 2.08 | 8.33% |
| TBE | 0.03 | 0.00% |
| ECA | 15.09 | 4.43% |
| SC | 60.83 | -0.44% |
| PRE | 0.64 | 0.00% |
| ELD | 1.62 | -6.90% |
| MFC | 25.94 | -0.04% |
| CPG | 10.61 | 4.53% |
| BBD-B | 2.73 | -1.09% |
TSE Canada Top Gainers Stocks
TSE Canada Top Losers Stocks
| AEZ Daily Charts |
AEZ Intraday Charts |
Whats New @ Bazaartrend |
AEZ Free Analysis |
|
|
AEZ Important Levels Intraday
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
| RESISTANCE | 4.06 |
| RESISTANCE | 4.04 |
| SUPPORT | 4.00 |
| SUPPORT | 3.98 |
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
AEZ Target for Month February
| 4th UP TARGET | 0 |
| 3rd UP TARGET | 0 |
| 2nd UP TARGET | 0 |
| 1st UP TARGET | 0 |
| 1st DOWN TARGET | 0 |
| 2nd DOWN TARGET | 0 |
| 3rd DOWN TARGET | 0 |
| 4th DOWN TARGET | 0 |
AEZ Weekly Target
| 4th UP TARGET | 0.00 |
| 3rd UP TARGET | 0.00 |
| 2nd UP TARGET | 0.00 |
| 1st UP TARGET | 0.00 |
| 1st DOWN TARGET | 0.00 |
| 2nd DOWN TARGET | 0.00 |
| 3rd DOWN TARGET | 0.00 |
| 4th DOWN TARGET | 0.00 |
AEZ Target for Year 2021
| 4th UP TARGET | 0 |
| 3rd UP TARGET | 0 |
| 2nd UP TARGET | 0 |
| 1st UP TARGET | 0 |
| 1st DOWN TARGET | 0 |
| 2nd DOWN TARGET | 0 |
| 3rd DOWN TARGET | 0 |
| 4th DOWN TARGET | 0 |
AEterna Zentaris, Inc. ( TSE Canada Symbol : AEZ )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
AEZ Business Profile
Aeterna Zentaris Inc., a specialty biopharmaceutical company, develops and commercializes novel treatments in oncology and endocrinology worldwide. The companyÂ’s product pipeline includes MACRILEN, a product candidate for which the company has filed a New Drug Application to the FDA as an oral product used for evaluating adult growth hormone deficiency; and is also investigated in Phase 2A clinical trials to treat cancer-induced cachexia. Its product pipeline also comprises Zoptarelin doxorubicin, which has completed Phase 2 clinical trials to treat ovarian and endometrial cancer, and breast cancer; and Phase 1/2 clinical trials to treat bladder and prostate cancers. In addition, the companyÂ’s product candidates in clinical and preclinical development consist of AEZS-120, a live recombinant oral tumor vaccine candidate; PI3K/Erk inhibitors, including AEZS-129 and AEZS-136 for oncology; and disorazol Z product candidates, such as AEZS-137 and AEZS-125 for oncology. Aeterna Zentaris Inc. was founded in 1990 and is headquartered in Quebec City, Canada.
© 2005-2019 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
